Lígia Yukie Sassaki

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 224 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +12

Risankizumab for Ulcerative Colitis

Edouard Louis, Stefan Schreiber, Remo Panaccione et al. · JAMA · 2024 · 110 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Heda M B S Amarante et al. · World Journal of Gastroenterology · 2019 · 87 citations · Full text

Medicine, Health Sciences, Gastroenterology +13

<p>Cardiovascular Risk in Individuals with Inflammatory Bowel Disease</p>

Robertha Biondi, Péricles Sidnei Salmazo, Silméia Garcia Zanati Bazan et al. · Clinical and Experimental Gastroenterology · 2020 · 49 citations · Full text

Medicine, Health Sciences, Epidemiology +15